‍

A recent publication in Nature Reviews Drug Discovery highlights how pragmatic clinical trials and real-world evidence (RWE) are transforming precision oncology, making it faster and more cost-effective. The article underscores the role of PRIME-ROSE, a Horizon Europe-funded initiative, in streamlining Drug Rediscovery Protocol (DRUP)-like clinical trials (DLCTs) across multiple European countries.

By establishing a single gateway for sponsors, PRIME-ROSE enhances patient recruitment, harmonizes datasharing, and aligns outcome definitions, significantly accelerating research — particularly for rare cancer subgroups that often face slow trial enrollment.

Additionally, PRIME-ROSE enables real-world evidence (RWE) for example through the DigiONE digital oncology network, improving data quality and strengthening regulatory and payer acceptance of trial results. This approach enables the efficient, data-driven expansion of precision cancer treatments, potentially benefiting thousands of patients with actionable biomarkers.

‍

To learn more, read the full article: Accelerating precision oncology by converging pragmatic trials and real-world evidence

You can also download the pdf of the article below!